Dr Corless co-authored a study published in the J Clinical Oncology assessing the effects of imatinib

Knight Diagnostic Laboratories' Christopher Corless, MD and Carol Beadling, PhD are among the co-authors in a study just published in the J Clinical Oncology assessing the effects of imatinib (Gleevec) treatment in patients with melanomas with KIT mutations or amplifications. The Knight Diagnostic laboratories performed all of the genotyping for the clinical trial. Read more here.